Back to results
US 2022/0064302 A1Published application
Anti-PD-1 Binding Proteins and Methods of Use Thereof
AssigneeGigaGen, Inc.
InventorsDavid Scott Johnson, Adam Shultz Adler, Rena Aviva Mizrahi, Yoong Wearn Lim, Michael Asensio
Life of this patent
Estimating the term…
Abstract
Provided herein are antigen-binding proteins (ABPs) that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
Claims23
An isolated antigen binding protein (ABP) that specifically binds a human programmed cell death protein 1 (PD-1), comprising:
- (a) a CDR3-L having a sequence selected from SEQ ID NOS:
- 3001-3028 and a CDR3-H having a sequence selected from SEQ ID NOS:
- 6001-6028;
- or
- (b) a CDR3-L having a sequence selected from SEQ ID NOS:
- 10092-10614 and a CDR3-H having a sequence selected from SEQ ID NOS:
- 11661-12183;
- or
- (c) a CDR3-L having a sequence of the CD3-L of any one of the clones in the library deposited under ATCC Accession No. PTA-125509 and a CDR3-L having a sequence of the CD3-L of any one of the clones in the library deposited under ATCC Accession No. PTA-125509.
6 more elements
The ABP of any of the above claims, wherein the ABP binds human PD-1 with a KD of less than 500nM, as measured by bio-layer interferometry or surface plasmon resonance.
Dependencies are inferred from the claim text.